Performance of the ASAS Classification for Axial and Peripheral Spondyloarthritis in an Established Clinical Cohort: Comparison with Criteria Sets of Amor and the ESSG
P.P. Cheung, S. Paternotte, V. Burki, A. Durnez, M. Elhai, I. Fabreguet, et al. ........................................... 816

Preliminary Validation of a Self-reported Screening Questionnaire for Inflammatory Back Pain

In Vivo Peripheral Blood Proinflammatory T Cells in Patients with AS

Clinical Efficacy of Etanercept Versus Sulfasalazine in AS Subjects with Peripheral Joint Involvement

Nail Disease in PsA: Distal Phalangeal Bone Edema Detected by MRI Predicts Development of Onycholysis and Hyperkeratosis
N. Dalbeth, K. Pui, M. Lobo, A. Doyle, P.B. Jones, W.J. Taylor, F.M. McQueen .................................................. 841

Construct Validity of the Modified Numeric Rating Scale of Patient Global Assessment in PsA

Identification of the Clinical Features Distinguishing PsA and Fibromyalgia
A. Marchesoni, F. Atzeni, A. Spadaro, E. Lubrano, G. Provenzano, A. Cauli, et al ............................................... 849

Pediatric Rheumatology
Parent and Child Acceptable Symptom State in JIA
G. Filocamo, A. Consolaro, B. Schiappapietra, N. Rupert, A. Pistorio, N. Solari, et al ....................................... 856

Efficacy and Limitation of Infliximab Treatment for Children with Kawasaki Disease Intractable to IVIG Therapy: Report of an Open-label Case Series

Images in Rheumatology
Gouty Arthritis of the Ankle Masquerading as a Talus Fracture
M. Yang, B. Guo, D. Liang, D. Shi, L. Yang, J. Cao ................................................................. 868

Correspondence
Posterior Reversible Encephalopathy Syndrome
A. Ortiz, S. Roverano, S. Paira ............................................. 869

Could Increased VEGF Induced by IL-17 Be the Cause of Posterior Reversible Encephalopathy Syndrome in SLE?
S.J. Park, K.S. Pai, J.H. Kim, J.I. Shin ............................................. 870

Reply
I.R. Varaprasad, S. Agrawal ............................................. 871

High-titer Anti-aquaporin-4-IgG-associated Myelitis in Rheumatic Syndrome
S. Sciascia, D. Roccatello, D. Rossi, A. Russo, M.O. Mereuta, R. Cavallo ............................................. 871

Reply
A.R. Chogle ............................................. 873

Clarification of the Modified Radiographic Damage Scoring Method for Gout
N. Dalbeth, F.M. McQueen ............................................. 874

Reply
J-Y. Choe, S-K. Kim ............................................. 874

Letters
Clinical Relevance of MEFV Gene Mutations in Japanese Patients with Unexplained Fever
K. Migita, H. Ida, H. Moriuuchi, K. Agematsu ............................................. 875

Does a Joint Count Calibration Exercise Make a Difference? Implications for Clinical Trials and Training
L.K. Stamp, A. Harrison, C. Frampton, M.M. Corkill ............................................. 877

Amyloidosis and Giant Cell Arteritis/Polyarteritis Rheumatica
K. Legault, A. Shroff, M. Crowther, N. Khalidi ............................................. 878

Teaching Basic Rheumatology
I. Kushner ............................................. 880

Corrections
Scleritis: A Paradoxical Effect of Etanercept?
Etanercept-associated Inflammatory Eye Disease

Dysregulation of the Microvasculature in Nonlesional Non-Sun-exposed Skin of Patients with Lupus Nephritis

Meetings in Rheumatology ............................................. x